Plasma derivative · BLA
Hizentra (Human immunoglobulin g) NDC 44206-456
Human immunoglobulin g .2 g/mL · Liquid · Subcutaneous · CSL Behring AG
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 44206-456-21 | 4420604562144206045621 | 1 SYRINGE in 1 CARTON (44206-456-21) / 5 mL in 1 SYRINGE (44206-456-94)Marketed from Jan 1, 2020 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Hizentra
- Generic name (nonproprietary)
- human immunoglobulin g
- Active ingredients
- Human immunoglobulin g — .2 g/mL
- Dosage form
- Liquid
- Route
- Subcutaneous
- Labeler
- CSL Behring AGNDC labeler code 44206
- Product type
- Plasma derivative
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 125350
- Marketing start
- Listing expires
- Other FDA classes
- Antigen Neutralization (Mechanism)Immunoglobulins (Chemical structure)Passively Acquired Immunity (Physiologic effect)
- Identifiers
- Product ID 44206-456_411c01a7-0ae7-45d2-8b4c-cbe99a2ba264SPL ID 411c01a7-0ae7-45d2-8b4c-cbe99a2ba264
- Pharmacologic class
- Human Immunoglobulin G
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N444206045621followed by a unit qualifier and the quantityPackage 44206-0456-21. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
The FDA listing for this product does not reference a label (SPL) set.
About NDC 44206-456
- What is NDC 44206-456?
- 44206-456 is the product NDC for Hizentra (human immunoglobulin g), Human immunoglobulin g .2 g/mL liquid, listed with the FDA by CSL Behring AG. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Hizentra (Human immunoglobulin g).
- What is the active ingredient?
- Human immunoglobulin g.
- Who is the labeler?
- CSL Behring AG, NDC labeler code 44206. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Hizentra?
- 6 other product NDCs are listed under this name. See all Hizentra NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Hizentra products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-457 | 44206-0457-22 |
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-458 | 44206-0458-24 |
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-451 | 44206-0451-01 |
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-452 | 44206-0452-02 |
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-454 | 44206-0454-04 |
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-455 | 44206-0455-1044206-0455-25 |
Other NDCs under BLA 125350
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-451 |
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-452 |
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-454 |
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-455 |
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-457 |
| Hizentrahuman immunoglobulin g | Human immunoglobulin g .2 g/mL | LiquidSubcutaneous | CSL Behring AG | 44206-458 |